Regeneron earns a buy rating with strong profit margins, low debt, and growth potential. Discover why shares may see a 39% ...

BioRewards Plasma Services ("BioRewards"), a next-generation plasma collection company, has officially launched with the backing of Alpha-1 Plasma Holdings ("Alpha-1"), a premier investor in plasma ...

Morning! Today we start with some breaking newss: Novo Nordisk’s CEO is stepping down. We also discuss a new, tailored CRISPR treatment for an infant with a deadly disease, how Amgen owes Regeneron ...

DZ Bank has significantly reduced its holdings in Regeneron Pharmaceuticals, offloading 74.4% of its shares in Q4. Despite ...

Regeneron’s fund will be independently managed by former Regeneron executives Jay Markowitz and Michael Aberman, said the company, which said the primary interest of the new fund is in ...

Deutsche Bank AG boosted its stake in Regeneron Pharmaceuticals by nearly 22% in Q4, now holding 539,269 shares valued at ...

Alabama‘s Tommy Tuberville trades more stocks than any other member of the U.S. Senate, finding himself on lists of top ...

Quarter ResultsFormycon reports strong operational performance and financial results for first quarter of 2025 12.05.2025 / 06:30 CET/CESTThe issuer is solely responsible for the content of this ...

Regeneron (REGN) wins $400M in damages as jury finds Amgen (AMGN) violated antitrust laws by promoting its heart drug Repatha ...

Regeneron Pharmaceuticals won $406.8 million in damages for a lawsuit claiming Amgen violated antitrust and tort laws. A jury in a Delaware court found that Amgen violated certain laws, and gave ...

Fintel reports that on May 14, 2025, Citigroup upgraded their outlook for Regeneron Pharmaceuticals (NasdaqGS:REGN) from ...

A federal jury found Amgen liable for violating antitrust and tort laws. Elsewhere, Allogene and Kyverna trimmed staff and ...